BioMark Diagnostics【BUX】銘柄情報

BioMark Diagnostics Inc (BUX) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.55

( 1.85% )

買値

0.54

売値

0.55

出来高

7,500

0.55 日の範囲 0.55

0.27 52 週間の範囲 0.64

時価総額

57.8M

前日終値

0.54

始値

0.55

時刻

2500

0.55

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 4,687

発行済株式数

105,090,213

配当利回り

PER

-31.58

1 株当たり利益 (EPS)

-0.02

歳入

91.77k

純利益

-1.7M

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck canc... Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada. 詳細を表示

セクター

Healthcare

業界

Medical Diagnostics & Screening

ウェブサイト

www.biomarkdiagnostics.com

本社

Richmond, Canada

設立

2026

BioMark Diagnostics Inc is listed in the Healthcare sector of the Canadian Securities Exchange with ticker BUX. The last closing price for BioMark Diagnostics was $0.54. Over the last year, BioMark Diagnostics shares have traded in a share price range of $ 0.27 to $ 0.64.

BioMark Diagnostics currently has 105,090,213 shares in issue. The market capitalisation of BioMark Diagnostics is $57.80 million. BioMark Diagnostics has a price to earnings ratio (PE ratio) of -31.58.

BioMark Announces Progress Towards Data Analysis

VANCOUVER, British Columbia, Feb. 16, 2016 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. (“BioMark”) (CSE:BUX) (FSE:20B) (OTCQB:BMKDF...

BioMark Diagnostics to Conduct Validation Studies for Its Patented Assays in Patients With Lung Cancer

VANCOUVER, British Columbia, Sept. 10, 2015 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. ("BioMark") (CSE:BUX) (FSE:20B) (OTCQB:BMKDF) announces...

BioMark Diagnostics Receives Clearance From Health Canada to Commence Clinical Trial With Patented Non-Invasive, Urine-Based ...

VANCOUVER, British Columbia, Sept. 9, 2015 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. ("BioMark") (CSE:BUX) (FSE:20B) (OTCQB:BMKDF) announces...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.01	1.85185185185	0.54	0.55	0.54	4080	0.5495098	CS
4	-0.05	-8.33333333333	0.6	0.61	0.54	5325	0.56360075	CS
12	-0.06	-9.83606557377	0.61	0.61	0.54	3884	0.5760681	CS
26	0.09	19.5652173913	0.46	0.64	0.42	8850	0.52810194	CS
52	0.23	71.875	0.32	0.64	0.27	12597	0.4180792	CS
156	0.24	77.4193548387	0.31	0.64	0.17	13063	0.30787319	CS
260	0.305	124.489795918	0.245	0.64	0.15	15870	0.26872017	CS